Long-Term Safety of Lisocabtagene Maraleucel for CLL/SLL
This observational study is looking at the long-term safety of lisocabtagene maraleucel (liso-cel), a CAR T-cell therapy, in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). You may be able to join if you are 18 or older and have already received at least one infusion of lisocabtagene maraleucel for your CLL or SLL, according to its approved use. The main goal is to track any side effects over a long period, up to 15 years. The study aims to enroll 300 participants, but its current recruitment status is unclear.
- Study design
- This is an observational study, meaning researchers will gather information from 300 participants who have already received lisocabtagene maraleucel. It is not a randomized trial.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for adverse events (side effects) for up to 15 years after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Bristol-Myers Squibb · STUDY_DIRECTOR · Bristol-Myers Squibb
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Exclusion
What this trial measures
- Adverse events (AEs)Up to 15 years